Study to Assess the Effect of Macitentan on the Electrocardiogram (ECG) in Healthy Male and Female Subjects
Completed
Actelion
Phase 1
2011-08-01
The study is intended to demonstrate that macitentan does not have an effect on cardiac
repolarization exceeding the threshold of regulatory concern after repeated administration of
daily oral doses of 10 and 30 mg to healthy male and female subjects.
Prospective observational drug registry developed to characterize the safety profile
(including primarily potential serious hepatic risks) and to describe clinical
characteristics and outcomes of patients newly treated with Opsumit in the post-marketing
setting.
Comparison of the Pharmacokinetic Properties of Two Tablet Formulations of Macitentan in Healthy Adults
Completed
Actelion
Phase 1
2015-08-01
A study conducted in healthy adults to investigate if a new macitentan tablet leads to the
same fate of macitentan in the body (time of onset, time of presence, amount in the blood) as
the marketed macitentan tablet.
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
Terminated
Actelion
Phase 2
2015-07-01
This is a pilot study to assess the safety and efficacy of macitentan in patients with
pulmonary hypertension of sickle cell disease. This study will enroll approximately 10
subjects. Study participation for each subject will last approximately 24 weeks from
screening to end of treatment follow-up.
Macitentan in Pulmonary Hypertension of Sickle Cell Disease
Terminated
Boston University
Phase 2
2015-07-01
This is a pilot study to assess the safety and efficacy of macitentan in patients with
pulmonary hypertension of sickle cell disease. This study will enroll approximately 10
subjects. Study participation for each subject will last approximately 24 weeks from
screening to end of treatment follow-up.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
